Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.

CONCLUSION: Rifaximin significantly improved cognition and reduced endotoxin activity without significantly affecting the composition of the gut microbiome in patients with decompensated cirrhosis. PMID: 29307995 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/29307995?dopt=Abstract

Source: World Journal of Gastroenterology : WJG - December 21, 2017 Category: Gastroenterology Authors: Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H Tags: World J Gastroenterol Source Type: research